Three-year melanoma data gives Evaxion's AI-designed vaccine its best evidence yet, but partnership or non-dilutive capital is the condition that determines whether it reaches a registrational trial

Evaxion is an early-stage biotech company developing an AI-designed personalized cancer vaccine for advanced melanoma that is not yet approved.

EVX-01, Evaxion's personalized neoantigen vaccine for advanced melanoma, posted 75% ORR with 92% response durability at two years across 16 patients, the strongest clinical signal the company has generated. The thesis resolves on whether that Phase 2 dataset, generated in a small single-arm trial, is compelling enough to attract a partner or regulatory agreement supporting a registrational path before the H2 2027 runway runs out. The primary risk is that the small, uncontrolled trial design leaves approvability unresolved, and approved TIL therapy from Iovance (lifileucel) and oncolytic virus from Replimune (RP1) already occupy the post-checkpoint melanoma space EVX-01 would enter.